Form 4: BioLife Solutions CSO Sells Shares for Tax Obligations
Insider Transaction Report
BioLife Solutions' EVP & Chief Scientific Officer, Aby J. Mathew, sold 529 shares of common stock to cover tax withholding obligations.
Summary
- Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions Inc. (BLFS), reported a sale of common stock.
- The transaction involved the disposition of 529 shares of BLFS common stock.
- The shares were sold at a price of $20.74 per share.
- Following this transaction, Mathew beneficially owns 392,937 shares of common stock.
- The sale was executed on March 3, 2026, under a Rule 10b5-1(c) trading plan established on February 24, 2022.
- The purpose of the sale was to satisfy tax withholding obligations related to the vesting of restricted stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine, pre-planned transaction for tax purposes and does not indicate a change in the executive's confidence or the company's fundamentals.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that insider sales for tax withholding purposes, especially when executed under a pre-arranged 10b5-1 plan, are common occurrences and typically do not reflect a change in management's outlook on the company's prospects. This is a routine compliance filing.
Stakeholder Impact
- Minimal direct impact on shareholders as this is a small, routine sale for tax purposes by an executive, pre-planned under a 10b5-1 plan.
- No direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 02-24-2022 | Date Rule 10b5-1(c) trading plan was adopted by Aby J. Mathew. |
| 03/03/2026 | Date of the reported transaction (sale of common stock). |
| 03/05/2026 | Date the Form 4 was signed by Aby J. Mathew. |
Recommendation
holdThis Form 4 filing details a routine, pre-planned sale of a small number of shares by an executive to cover tax obligations associated with restricted stock vesting. Such transactions are common and typically do not reflect a change in the executive's long-term view of the company or its prospects. Therefore, it provides no new fundamental information to warrant a change in investment recommendation; a 'hold' stance is appropriate based solely on this filing.
Keywords
BioLife Solutions, BLFS, Aby J. Mathew, Insider Trading, Form 4, Stock Sale, Tax Withholding, Rule 10b5-1 Plan, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.